Navigation Links
Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
Date:4/20/2009

PITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of five antiretroviral (ARV) drugs used in second-line HIV/AIDS treatment regimens. Matrix also has been selected as the primary supplier of seven ARVs used for pediatric treatment.

Mylan Vice Chairman and CEO Robert J. Coury said: "I would like to congratulate UNITAID and CHAI on the tremendous impact they have made in fighting the HIV/AIDS epidemic, which continues to present significant challenges on a global scale. Facilitating patient access to affordable, quality treatments has helped transform AIDS from a fatal illness into a manageable chronic condition. Ensuring that access to these treatments continues to expand is a critical piece of solving this crisis. Mylan and Matrix are proud to play an important role in these efforts by supplying a broad portfolio of low cost, high quality products, and we remain committed to further increasing access for patients in developing countries through our innovative science and expertise."

According to the Joint United Nations Program on AIDS (UNAIDS), an estimated 33 million people in the world are infected with HIV, and more than 90% of those patients live in the developing world. Less than 4 million patients globally are receiving treatment; however, approximately 30% of patients in developing countries depend on Matrix ARV products.

Mylan's Chief Operating Officer Heather Bresch added: "Matrix has done a remarkable job developing a world-class ARV business in just a few years. Their emphasis on producing affordable products has significantly reduced the aver
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mich. Every day, their baby stopped breathing, his ... his lungs. April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good ... Gionfriddo, about her now 20-month-old son, Kaiba. "At that ... would take it and run with it." , They ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... N.Y. , May 23, 2013  BioScrip, Inc. ... Company will present at the Jefferies 2013 Global Healthcare ... Grand Hyatt New York. Richard ... Hai Tran , Chief Financial Officer, ... a.m. Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... and fight Human Immunodeficiency Virus (HIV) infections, today announced ... 30, 2011. GeoVax reported a net loss ... ended September 30, 2011, compared to $644,666 ($0.04 per ...
... Theravalues, a Japan based bio-venture, announced today ... prevention of heart failure and its progression for the ... started with the registration in July 2010, conducted by ... and University of Shizuoka, Japan, the researchers found that ...
... Research has expanded its research footprint to support ... offering high-quality biospecimens coupled with unprecedented premium data ... with AdeptBio, LLC ( http://www.adeptbio.com ).   ... services as needed to facilitate prospective collections of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients 2ACORN Research, LLC Announces Partnership with AdeptBio, LLC 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... DC Cancer researchers at Georgetown University,s Lombardi Comprehensive ... they say shuts down growth of human glioblastoma tumors ... of brain cancers; there is no effective treatment. In ... researchers demonstrate how this antibody latches onto a receptor ...
... joined forces in a groundbreaking assessment of the status of ... fishery ecosystem scientist from the CSIRO Wealth from Oceans Flagship, ... report on a two-year study, led by US scientists Dr ... the University of Washington. The study shows that steps ...
... A new approach to windows that could let in ... to 99% in buildings in Tropical regions without losing ... the International Journal of Engineering Systems Modelling and ... in the School of Environment, Resources and Development, at ...
Cached Biology News:Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 2Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 3Global curbs on overfishing are beginning to work 2Opening a new window on daylight 2
with GlutaMAXIL-glutamine...
Request Info...
... peptide derived from the C terminal region ... This peptide sequence is downstream from the ... Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin 36-transfected ...
Request Info...
Biology Products: